Mass Cytometry (CyTOF) Technology in Cancer Drug Research
Dr Charis Teh and her team have recently published multiple research papers using sophisticated science, particularly mass cytometry technology (CyTOF). Charis is committed to ensuring the future treatment of blood cancers are tailored to a particular patient profile and decrease the chance of relapse.
The ability to match each cancer to the ideal treatment would be invaluable. Dr Teh is a medical researcher that attempts to do this by identifying the ‘kill switch’ that triggers cell suicide in blood cancers. Using cutting-edge technology, she profiles an extensive network of life and death proteins in cancer cells to discover the most potent druggable killers in blood cancers. A Senior Postdoctoral Fellow at the Walter and Eliza Hall Institute of Medical Research (WEHI), Dr Teh holds a PhD from the ANU, a Master in Public Health from the University of Sydney and a BSc (Hons) from the Australian National University. She completed her postdoctoral training at Stanford University (USA), mastering the mass cytometry (CyTOF) technology and pioneered the use of this technology in Melbourne, Australia.
Dr Teh has published 22 papers and secured >$1M of competitive funding. Her 18 prestigious awards include an Australia-America Fulbright Scholarship, a Superstar of STEM, a National Fresh Science Award and a BD Science Communication Award. Dr Teh's growing reputation in the field has resulted in invitations to be a panelist/presenter at Victorian Comprehensive Cancer Centre Lunchtime Live, Melbourne Health Research Week and Diabetes Australia Expo. She partners with a local primary school to deliver science activities in classroom and hosts Scientific Discovery Tours at her institute. See Educator Profile